Clinical Trial

A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical Practice

Study acronym: G-START
Recruiting
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.
Trial Details
NCT Number NCT07746583
Lead Sponsor Janssen-Cilag Kft.
Conditions Psoriasis
Enrollment 100 participants
Start Date 2026-08-07
Primary Completion 2029-01-30 (estimated)
Study Completion 2029-02-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-05